NEFROZOL: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
NEFROZOL
Largest movements
- Receivables within one year +€147,198
up €147,198 (+7.8%), from €1.9m to €2.0m
- Trade debts +€145,109
up €145,109 (+7.5%), from €1.9m to €2.1m
- Gross operating margin +€8,447
up €8,447, from -€1,492 to €6,955
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €1,952,083 | €2,102,351 | +€150,269 | +7.7% |
| Current assets | 29/58 | €1,952,083 | €2,102,351 | +€150,269 | +7.7% |
| Amounts receivable within one year | 40/41 | €1,887,068 | €2,034,265 | +€147,198 | +7.8% |
| Trade receivables | 40 | €1,887,068 | €2,034,265 | +€147,198 | +7.8% |
| Cash at bank and in hand | 54/58 | €63,715 | €66,786 | +€3,071 | +4.8% |
| Deferred charges and accrued income | 490/1 | €1,300 | €1,300 | = | 0.0% |
| Total equity and liabilities | 10/49 | €1,952,083 | €2,102,351 | +€150,269 | +7.7% |
| Equity | 10/15 | €9,174 | €14,334 | +€5,160 | +56.2% |
| Contributions | 10/11 | €21,700 | €21,700 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€12,526 | -€7,366 | +€5,160 | +41.2% |
| Amounts payable | 17/49 | €1,942,908 | €2,088,017 | +€145,109 | +7.5% |
| Amounts payable within one year | 42/48 | €1,942,908 | €2,088,017 | +€145,109 | +7.5% |
| Trade debts | 44 | €1,942,908 | €2,088,017 | +€145,109 | +7.5% |
| Suppliers | 440/4 | €1,942,908 | €2,088,017 | +€145,109 | +7.5% |
| Other operating charges | 640/8 | €1,630 | €1,660 | +€31 | +1.9% |
| Gross operating margin | 9900 | -€1,492 | €6,955 | +€8,447 | |
| Operating profit (loss) | 9901 | -€3,121 | €5,295 | +€8,416 | |
| Financial income | 75/76B | €0 | - | = | |
| Recurring financial income | 75 | €0 | - | = | |
| Financial charges | 65/66B | €132 | €135 | +€3 | +2.3% |
| Recurring financial charges | 65 | €132 | €135 | +€3 | +2.3% |
| Profit (loss) for the period before taxes | 9903 | -€3,253 | €5,160 | +€8,413 | |
| Profit (loss) for the period | 9904 | -€3,253 | €5,160 | +€8,413 | |
| Profit (loss) for the period to be appropriated | 9905 | -€3,253 | €5,160 | +€8,413 |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 20 October 2026 via checked.be.